Information for healthcare professionals from market surveillance of medicinal products
Pharmacovigilance in the spotlight
Learning from adverse reaction reports – cases from pharmacovigilance
The purpose of this new section is to use real-life case reports from Switzerland as a reminder of possible side effects that professionals should be aware of in day-to-day clinical practice. The only way to protect patients against undesirable effects is to take account of and report medicinal product risks.
24.10.2025
Intraoperative floppy iris syndrome | tamsulosin | alpha-1 adrenergic receptor antagonist | IFIS | flaccid iris | iris prolapse | lens loss | detached retina | endophthalmitis
12.09.2025
aseptic Meningitis | non-steroidal anti-inflammatories (NSAIDs) | ibuprofen | mefenamic Acid | Ponstan® | antibiotics (sulfonamides, penicillins) | sulfamethoxazole | trimethoprim | co-trimoxazole | Bactrim® forte | intravenous immunoglobulin (IVIg) | human immunoglobulin | Intratect® 10% | monoclonal antibodies
07.08.2025
Taste disorder | dysgeusia | ageusia | anosmia | sense of taste | gefapixant | celecoxib
27.06.2025
alterazioni della voce | raucedine | effetto collaterale ormonale | antagonista del recettore dei mineralcorticoidi | antagonista del recettore dell’aldosterone | recettore degli steroidi | recettore degli androgeni| recet-tore del progesterone | diuretico risparmiatore di potassio | antiandrogeno | spironolattone | aldactone | uso off-label | alopecia androgenetica | alopecia | ginecomastia | mastodinia | alterazioni della libido |disturbi mestruali | alte-razioni della potenza erettile
02.05.2025
Finasteride | erectile dysfunction | impaired concentration | loss of drive | persistent disorders | alopecia | androgenetic alopecia
07.04.2025
Palforzia | eosinophilic oesophagitis | eoe | eosinophilic granulocytes | difficulty swallowing | peanut allergy | allergy
24.03.2025
sartans | valsartan | NSAIDs | hyperkalaemia | electrolyte disorders
10.01.2025
Octenisept | wound disinfection | wound irrigation | tissue necrosis | octenidine | phenoxyethanol | myositis | fasciitis | medication error | tissue damage
2024 - 2022
22.11.2024
Medicinal product mix-up | medication error | insulin | Apidra | Lantus | hypoglycaemia | hypoglycaemic coma
01.11.2024
Sertraline | duloxetine | selective serotonin reuptake inhibitors | serotonin-noradrenaline reuptake inhibitors | colitis | diarrhoea
23.09.2024
SonoVue | anaphylactic reaction | shock | hypersensitivity | diagnostics | macrogol | sulphur hexafluoride | vasovagal reaction
30.08.2024
Suicidality | suicidal ideation | suicidal behaviour | antiepileptics | neuropathic pain | Lyrica | pregabalin | fluoroquinolones | Tavanic | levofloxacin | Ritalin | methylphenidate hydrochloride
22.07.2024
Isotretinoin | teratogenicity
28.05.2024
Eosinophilic pneumonia | daptomycin | antibiotics | staphylococci | antibiotic resistance
03.05.2024
Paxlovid | CYP3A4 | inhibitors | tacrolimus | narrow therapeutic range | trazodone | ritonavir | nirmatrelvir | COVID-19
22.04.2024
Methotrexate | overdose | pancytopenia | dose adjustment Rheumatoid arthritis | palliative therapy | stomatitis
19.02.2024
Vaccinations | tick-borne encephalitis (TBE) | basic immunisation | booster | Swiss vaccination plan
22.12.2023
Hormonal contraceptives | depression | estradiol | dienogest
17.11.2023
infants | vaccinations | hypotonia | hyporesponsive episode | apathy | HHE | basic immunisation | Swiss vaccination plan
29.09.2023
iron products | ferric carboxymaltose | parenteral iron | hypophosphataemia.
11.08.2023
Tizanidine | Sirdalud | pharmacokinetic interactions | drug interactions | muscle relaxant | antispasmodic agent | CYP1A2 inhibitors | fluvoxamine | ciprofloxacin
07.07.2023
Betaseptic | skin disinfection | burn | propanol | ethanol | povidone-iodine
01.06.2023
Contraceptive | venous thrombosis | pulmonary embolism | drospirenone | chlormadinone acetate
09.05.2023
Novalgin | metamizole | agranulocytosis
11.04.2023
Loperamide | overdose | drug dependency | opiate withdrawal symptoms | QT interval
08.02.2023
Pancreatitis | Ozempic | semaglutide | Imurek | azathioprine | isotretinoin
26.11.2022
Fluoroquinolones | moxifloxacin | iprofloxacin | levofloxacin | tendon rupture | Achilles tendon
21.11.2022
Hyperthyroidism | amiodarone | thyroiditis | iodine level
Swissmedic Vigilance-News
Topical aspects of medicinal product risk assessment
Twice a year, the Safety of Medicines Division reports on current topics relating to adverse reaction surveillance and the evaluation of safety signals. Swissmedic's "Vigilance News" appears twice a year as an online resource.
18.11.2025
In this edition, among others:
- Fluoroquinolone-associated disability
- Semaglutide and tirzepatide for weight management – updates on efficacy and harms
- Non-arteritic anterior ischemic optic neuropathy (NAION) in a patient treated with semaglutide
- Enhancing drug safety: the role of pharmacovigilance in paediatrics
- Summary of adverse events following immunization reported in Switzerland during 2024
15.05.2025
In this edition, among others:
- Late-onset immune-related AEs with immune checkpoint inhibitors
- Interstitial lung disease associated with abemaciclib
- PML, IRIS and S1PRM: Product Information update
- Valproate: Swiss individual case reports of CM and NDD
- Statistical review of the activities of the division Safety of Medicines 2024
25.11.2024
In this edition:
- Impact of sex on pharmacokinetics and pharmacodynamics
- Exposure to lithium during pregnancy
- Brugada syndrome and bupropion
- Stronger warnings about the risks associated with overuse of SABAs
- Statistical review 2023
28.05.2024
In this edition:
- Paclitaxel-induced cystoid macular oedema
- Chemotherapy-associated severe hypertriglyceridaemia
- Spider-like skin reactions following bortezomib (Velcade®)
- Potential increased risk of neurodevelopmental disorders (NDD) in children whose fathers were treated with valproate
28.05.2024
In this edition:
- Paclitaxel-induced cystoid macular oedema
- Chemotherapy-associated severe hypertriglyceridaemia
- Spider-like skin reactions following bortezomib (Velcade®)
- Potential increased risk of neurodevelopmental disorders (NDD) in children whose fathers were treated with valproate
